United States Patent 8,268,349: Ritonavir Solid-Dispersion Claims, Patent Scope, Expiration and Generic Risk

U.S. Patent No. 8,268,349 protects a narrowly defined ritonavir solid-dispersion dosage form. The core claim requires four material elements: sorbitan monolaurate, a water-soluble polymer with a glass-transition temperature of at least 50°C, colloidal silica, and ritonavir. The dosage form must contain 50% to 85% by weight of the polymer.

The strongest commercial protection is concentrated in claims 1, 2, 3, 4, and 5. Claims 6 and 7 add manufacturing-process limitations and are narrower. The patent does not cover every ritonavir formulation, every ritonavir solid dispersion, or every product using copovidone.

What does U.S. Patent 8,268,349 protect?

The patent protects a solid pharmaceutical dosage form containing a ritonavir-based solid dispersion with a high loading of a water-soluble polymer. The claimed formulation architecture is:

Required element	Claim requirement
Active pharmaceutical ingredient	At least one HIV protease inhibitor, comprising ritonavir
Lipid or surfactant component	Sorbitan monolaurate
Polymer	At least one pharmaceutically acceptable water-soluble polymer
Polymer thermal property	Glass-transition temperature of at least 50°C
Inorganic excipient	Colloidal silica
Polymer concentration	50% to 85% by weight of the total dosage form
Dosage-form structure	Solid dispersion
Optional narrower feature	Solid solution
Optional narrower process	Melt solidification, melt-extrusion, spray-drying or solution-evaporation

The claims are composition claims unless they expressly incorporate a process limitation. A competing manufacturer generally must satisfy every limitation of an asserted claim to infringe directly.

How should claim 1 of U.S. Patent 8,268,349 be construed?

Claim 1 is the broadest independent claim provided. Its scope depends on five principal issues.

1. "Comprising ritonavir" permits additional protease inhibitors

The phrase "comprises ritonavir" ordinarily makes ritonavir mandatory but does not exclude other HIV protease inhibitors. A formulation containing ritonavir and another protease inhibitor could fall within the claim if all other limitations are met.

A product containing only another protease inhibitor, without ritonavir, would not satisfy the express ritonavir limitation.

2. The polymer must be water-soluble and have a Tg of at least 50°C

The polymer limitation is functional and technical. It is not enough for the excipient to be pharmaceutically acceptable. It must also be water-soluble and have a glass-transition temperature of at least 50°C.

Copovidone is the principal polymer identified in the dependent claims. Other polymers could theoretically qualify, depending on their solubility, molecular characteristics, and measured Tg.

3. The 50% to 85% range is based on the entire dosage form

The claim measures polymer content against the total dosage-form weight, not merely the solid dispersion weight. A product with 49% polymer by total dosage-form weight would fall outside the literal numerical range of claim 1, subject to any applicable doctrine-of-equivalents analysis.

The range is commercially significant because it requires the polymer to constitute the principal mass of the dosage form.

4. Sorbitan monolaurate and colloidal silica are mandatory

Both excipients are required by claim 1. A ritonavir solid dispersion using copovidone but omitting sorbitan monolaurate or colloidal silica would not literally satisfy claim 1.

The patent therefore does not broadly control copovidone-based ritonavir dispersions as a class.

5. The dosage form must contain a solid dispersion

A conventional crystalline ritonavir tablet, a simple physical blend, a liquid formulation, or a dosage form containing ritonavir without a solid-dispersion structure would fall outside the express scope of claim 1.

What do claims 2 through 5 add?

Claims 2 through 5 create narrower formulation positions that are easier to analyze but cover fewer products.

Claim	Added limitation	Commercial effect
2	Polymer comprises copovidone	Targets the principal identified polymer
3	Sorbitan monolaurate is 2% to 20%; polymer is copovidone	Establishes a narrower quantitative formulation
4	Solid dispersion is a solid solution	Narrows the physical-state requirement
5	Claim 3 formulation is a solid solution	Narrowest principal composition claim provided

Claim 3 is potentially important in product testing because it combines a specific polymer with a defined sorbitan monolaurate range. A product that satisfies claim 1 but contains less than 2% or more than 20% sorbitan monolaurate may avoid claim 3 while remaining exposed to claim 1.

Claims 4 and 5 introduce the term "solid solution." That term can create claim-construction disputes over whether the active ingredient is molecularly dispersed within the polymer matrix or merely dispersed as a separate amorphous or crystalline phase. Analytical evidence may include powder X-ray diffraction, differential scanning calorimetry, spectroscopy, microscopy, and dissolution behavior.

What do claims 6 and 7 protect?

Claims 6 and 7 address manufacturing routes.

Claim 6: melt-solidification process

Claim 6 requires a dosage form of claim 1 prepared by solidifying a melt containing:

sorbitan monolaurate;
the water-soluble polymer; and
ritonavir.

This claim is narrower than claim 1 because it adds a specific process history. It may be relevant to products manufactured through hot-melt processing even if the final dosage form is structurally difficult to distinguish from another solid dispersion.

Claim 7: alternative dispersion processes

Claim 7 covers a dosage form of claim 1 in which the solid dispersion is prepared by:

melt-extrusion;
spray-drying; or
solution-evaporation.

The alternatives are disjunctive. A product made by any one of the listed methods can satisfy the process limitation if the underlying composition also satisfies claim 1.

A manufacturer using fluid-bed coating, direct compression, dry blending, or another unlisted process may avoid the literal wording of claim 7. That does not by itself avoid composition claims 1 through 5.

What formulation patents protect ritonavir products?

The 8,268,349 claims are directed to formulation technology rather than the basic pharmacological identity of ritonavir. The patent's technical focus is the creation of a solid dispersion intended to address formulation performance, including poor aqueous solubility and oral absorption.

The principal protected formulation concept is the combination of:

ritonavir;
a high concentration of copovidone or another qualifying polymer;
sorbitan monolaurate; and
colloidal silica.

This combination differs from broad claims directed solely to ritonavir, HIV protease inhibition, or treatment of HIV infection.

The patent also differs from a conventional method-of-use patent. None of the provided claims requires administration to a patient, treatment of HIV, a dosage regimen, or coadministration with another antiviral. The claims are product and manufacturing claims.

What is the patent landscape for ritonavir?

Ritonavir's patent landscape includes several distinct categories:

Patent category	Typical subject matter	Relationship to U.S. 8,268,349
Active-ingredient patents	Ritonavir compound and chemical synthesis	Separate from the claimed dosage form
Drug-use patents	HIV treatment or pharmacokinetic boosting	Not covered by the provided claims
Solid-dispersion patents	Amorphous or polymeric ritonavir systems	Potentially overlapping technical field
Formulation patents	Tablets, capsules, excipients and manufacturing methods	Directly relevant
Combination patents	Ritonavir with other antivirals	Relevant only if formulation limitations are met
Process patents	Melt-extrusion, spray-drying and solvent processing	Potential overlap with claims 6 and 7
Product-specific patents	Branded or reformulated ritonavir products	Requires separate product and Orange Book analysis

Abbott Laboratories developed ritonavir, and AbbVie became the successor commercial organization for many Abbott pharmaceutical assets. Corporate succession does not itself establish ownership of this particular patent. The recorded assignee and current ownership should be taken from the USPTO assignment database and the patent's maintenance records.

When does U.S. Patent 8,268,349 lose exclusivity?

The patent issued on September 18, 2012. Its underlying application traces to a 2004 priority period. On a standard 20-year patent-term calculation, the base term would run to approximately December 2025, subject to patent-term adjustment, terminal disclaimers, or other term events recorded by the USPTO.[1]

The key timing points are:

Event	Date or period
Earliest reported priority period	December 2004
U.S. patent issue	September 18, 2012
Standard base-term endpoint	Approximately December 2025
Possible adjustment	USPTO patent-term adjustment controls
Patent-term extension	No extension is established by the claim text

The relevant legal date is the enforceable expiration date in the USPTO patent-term record, not simply the issue date or the earliest priority date.

What is the Orange Book status of U.S. Patent 8,268,349?

A patent's inclusion in the FDA Orange Book is separate from patent issuance and ownership. The Orange Book lists patents submitted for approved drug products under FDA procedures, but it does not list every patent that could be asserted against a formulation manufacturer.[2]

For ritonavir, the relevant reference products include Norvir tablets, capsules, and oral solution, depending on the applicable NDA and dosage form. A formulation patent must be matched to the approved product and NDA before it can create a statutory Paragraph IV certification issue.

The provided patent claims do not establish:

the NDA to which the patent was submitted;
the listed dosage form;
the Orange Book patent-use code;
the delisting date;
whether the patent was subject to a current Paragraph IV certification; or
whether any listed patent term had expired.

The formulation-specific nature of the claims makes Orange Book relevance product-dependent. A patent directed to a particular solid dosage form may be more relevant to a tablet or capsule ANDA than to a liquid ritonavir product.

Which companies are challenging the patent?

A Paragraph IV challenge requires an ANDA applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. The patent claims alone do not identify an ANDA filer, litigation defendant, case number, or settlement.

No challenger, district-court action, Federal Circuit appeal, or settlement agreement can be attributed to U.S. 8,268,349 solely from the claim language. Any litigation analysis must distinguish:

challenges to ritonavir compound patents;
challenges to Norvir formulation patents;
challenges to combination products such as HIV protease-inhibitor regimens; and
challenges to later antiviral products that use ritonavir only as a pharmacokinetic booster.

A Paragraph IV certification against a different ritonavir patent would not automatically challenge U.S. 8,268,349.

How strong is the patent estate for U.S. Patent 8,268,349?

The patent has a focused but potentially meaningful formulation position.

Strengths

Claim 1 combines a specific active ingredient with a defined excipient architecture.
The 50% to 85% polymer range may capture commercially practical high-polymer dispersions.
Claims 2 and 3 expressly target copovidone formulations.
Claims 6 and 7 provide process-based positions for common dispersion technologies.
Colloidal silica and sorbitan monolaurate create additional formulation-specific barriers.

Weaknesses

Every required component must be present for literal infringement.
The claim does not cover ritonavir formulations that omit sorbitan monolaurate or colloidal silica.
The polymer must meet both the water-solubility and Tg requirements.
Claims 4 and 5 may depend on a contested definition of "solid solution."
Process claims may be difficult to prove without manufacturing records or technical evidence.
The base patent term is near or at its scheduled endpoint under the standard 20-year calculation.

The patent's commercial value is therefore highest against a product that closely replicates the claimed high-polymer, copovidone-based solid-dispersion platform.

What generic entry risks exist for ritonavir products?

A generic manufacturer faces different risks depending on its formulation and filing strategy.

Generic design	Risk under U.S. 8,268,349
Ritonavir tablet with no solid dispersion	Low literal risk
Solid dispersion without sorbitan monolaurate	Low literal risk
Solid dispersion without colloidal silica	Low literal risk
Copovidone dispersion with both required excipients	High risk if polymer is 50% to 85%
Copovidone dispersion with 2% to 20% sorbitan monolaurate	Highest risk under claims 1 to 3
Spray-dried qualifying dispersion	Potential claim 7 risk
Melt-extruded qualifying dispersion	Potential claims 6 and 7 risk
Liquid ritonavir formulation	Generally outside the provided dosage-form claims
Different polymer below the Tg threshold	Potential design-around, subject to testing

A design-around strategy could change the polymer, remove colloidal silica, replace sorbitan monolaurate, alter polymer loading, or use a non-solid-dispersion formulation. Each change must be evaluated against the full claim set and any separate patent families.

How does this patent compare with method-of-use and biosimilar protection?

This is a small-molecule formulation patent. Biosimilar rules do not apply because ritonavir is a chemically synthesized active ingredient, not a biologic subject to the Biologics Price Competition and Innovation Act.

The patent also does not provide method-of-use protection based on the supplied claims. It does not require a therapeutic indication, HIV viral-load reduction, protease inhibition in a patient, or pharmacokinetic boosting of another drug.

Its protection is strongest at the manufacturing and dosage-form level, not at the clinical-use level.

What licensing and settlement issues affect the patent?

Abbott and AbbVie corporate transactions affect asset history but do not prove a third-party license. The claim text also provides no evidence of an exclusive license, co-development agreement, covenant not to sue, Paragraph IV settlement, or authorized-generic arrangement.

For commercial diligence, the relevant documents are assignment records, FDA patent listings, ANDA litigation dockets, settlement filings, and any license recorded in transaction or regulatory materials. A settlement concerning another ritonavir patent should not be treated as a settlement of U.S. 8,268,349.

Key Takeaways

U.S. 8,268,349 is a formulation and manufacturing patent focused on ritonavir solid dispersions.
Claim 1 requires sorbitan monolaurate, colloidal silica, a qualifying water-soluble polymer, ritonavir, and 50% to 85% polymer by total dosage-form weight.
Claims 2 and 3 target copovidone formulations, with claim 3 adding a 2% to 20% sorbitan monolaurate range.
Claims 4 and 5 require a solid solution.
Claims 6 and 7 address melt solidification, melt-extrusion, spray-drying, and solution-evaporation.
The patent does not cover all ritonavir products or all ritonavir solid dispersions.
The standard base patent term appears to run to approximately December 2025, subject to USPTO term adjustments.
Orange Book relevance depends on whether the patent was listed against the applicable ritonavir NDA and dosage form.
No Paragraph IV challenger, litigation outcome, or settlement can be established from the claim text alone.
Biosimilar risk is not applicable; the relevant competitive threat is generic small-molecule entry.
The main design-around options involve excipient selection, polymer loading, physical form, or manufacturing route.

FAQs

Can a ritonavir tablet infringe U.S. Patent 8,268,349 without copovidone?

Yes. Claim 1 does not require copovidone specifically. It requires a water-soluble polymer with a Tg of at least 50°C. Copovidone is required only by claims 2, 3, and 5.

Does a ritonavir formulation infringe if it contains sorbitan monolaurate but no colloidal silica?

It would not literally satisfy claim 1 because colloidal silica is a required element. The formulation could still implicate other patents or, in limited circumstances, an equivalents theory.

Are liquid Norvir formulations covered by these claims?

The provided claims require a solid pharmaceutical dosage form and a solid dispersion. A conventional liquid formulation would generally fall outside their literal scope.

Does use of spray-drying automatically create infringement?

No. Spray-drying is relevant to claim 7 only when the resulting dosage form also satisfies the claim 1 composition requirements.

Can a generic avoid the patent by using another HIV protease inhibitor?

If the product contains no ritonavir, it would not satisfy the express "comprises ritonavir" limitation. Other patents may still apply to the substitute protease inhibitor.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,268,349, pharmaceutical composition comprising a solid dispersion containing ritonavir. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term information. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products: Norvir (ritonavir) prescribing information. U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055734	⤷ Start Trial
Argentina	077411	⤷ Start Trial
Australia	2006216856	⤷ Start Trial
Brazil	122012031169	⤷ Start Trial
Brazil	PI0609173	⤷ Start Trial
Canada	2598827	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,268,349

Summary for Patent: 8,268,349